Compound class:
Synthetic organic
Comment: This compound is reported to disrupt the β-catenin/B-cell lymphoma 9 (BCL9) interaction, by binding to β-catenin [1]. It was designed to block Wnt signalling and expression of oncogenic Wnt target genes, as a mechanism to target colorectal cancer. Since approximately 80% of colorectal cancers carry activating Wnt/β-catenin pathway mutations, this pathway is an active molecular target for oncology therapeutic development.
The chemical structure shown here is used to represent the racemic mixture of (S)-41 and (R)-41. Experiments comparing the in vitro activities of the isolated enantiomers and the racemate, showed that the chiral centers in the molecule do not significantly alter its binding interaction with β-catenin [1]. |
|
Selectivity at ligand targets | ||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||
|